Background: Because systemic lupus erythematosus (SLE) affects women of reproductive age, pregnancy is a major concern.
S
ystemic lupus erythematosus (SLE) primarily affects women of childbearing age. Without treatment with cytotoxic agents, SLE does not adversely affect fertility (1, 2), but fetal and maternal health during pregnancy are concerns. Advice about safety and timing of pregnancy requires identification of clinical and laboratory variables that predict outcomes.
It has been suggested that pregnancies in women with SLE result in higher rates of preterm birth, preeclampsia, and fetal loss than in healthy women (3) (4) (5) (6) (7) (8) (9) (10) . Previous studies have identified active disease, hypocomplementemia, presence of anti-double-stranded DNA (dsDNA) antibodies, prior nephritis, and presence of antiphospholipid antibodies (aPLs) (6 -8, 10 -13) as risk factors for adverse pregnancy outcomes (APOs). The effects of pregnancy on SLE activity and the contribution of disease activity to APOs are unclear (10, 14 -18) . Currently, patients with SLE are advised to consider pregnancy during periods of minimal and stable disease (19) . However, data supporting this advice are based on retrospective or prospective single-center studies involving few patients, have limited generalizability to multiethnic populations, and are controversial (3) (4) (5) (6) (7) (8) (9) (10) .
To develop more robust data to inform patients and their physicians about pregnancy in women with SLE, we leveraged the PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study. PROMISSE is the largest multicenter, multiethnic, and multiracial study to prospectively assess the frequency of APOs, clinical and laboratory variables that predict them, and pregnancy-associated flare rates in women with inactive or mild/moderate SLE at conception.
control participants were designed to minimize factors unrelated to SLE that might affect outcomes. This article focuses on patients with SLE with or without aPLs (Appendix Figure, available at www.annals.org). Those with aPLs with or without SLE were previously reported (21) .
Patient Population
Pregnant patients were enrolled between September 2003 and December 2012 at 8 sites in the United States and 1 in Canada. Institutional review boards approved the protocol and consent forms, and written, informed consent was obtained from patients. Consecutive pregnant women meeting inclusion criteria were recruited up to 12 weeks' gestation, which precluded ascertainment of first-trimester losses. Only 1 pregnancy for each patient was included.
Inclusion criteria for enrollment were singleton intrauterine pregnancy, age 18 to 45 years, and hematocrit greater than 26%. Because the overall goal of PROMISSE was to identify risk factors for and mechanisms of APOs specifically attributable to lupus, aPLs, or both, exclusion criteria were based on the following potential causes of APOs: prednisone use greater than 20 mg/d, urinary protein-creatinine ratio greater than 1000 mg/g, erythrocyte casts on urinalysis, serum creatinine level greater than 1.2 mg/dL, diabetes mellitus, and blood pressure greater than 140/90 mm Hg at screening.
Definition of SLE Disease Activity and Flares During Pregnancy
Investigators used the Systemic Lupus Erythematosus Pregnancy Disease Activity Index (SLEPDAI), an instrument incorporating history, physical examination, and laboratory measures to gauge lupus activity. The SLEPDAI was modified to discount physiologic changes in pregnancy that mimic disease activity to ensure attribution to lupus (19, 22, 23) .
A composite was used to define flares as mild/ moderate or severe. The composite was similar to that used in the SELENA (Safety of Estrogens in Lupus Erythematosus, National Assessment) trial, except SLEP-DAI was substituted for the SLEDAI (24) instrument used in the SELENA trial. The composite included SLEPDAI score; assessment of new or worsening disease activity, medication changes, and hospitalizations not captured in the SLEPDAI score; and Physician's Global Assessment (PGA) score (range of 0 [inactive disease] to 3 [severe disease]). Study investigators were trained with "paper" pregnant patients with SLE and case report forms prepared by one of the authors (gold standard). The average correlation among investigator responses with the gold standard was 0.89 (95% CI, 0.83 to 0.95), and mean scores were within ±15% of the gold standard. Interrater reliability estimated by the intraclass correlation coefficient was also high (0.78 [CI, 0.61 to 0.89]). In some situations, the SLEPDAI and PGA were not completed because required serologic or complete blood count data were unavailable. In those cases, flare status was based on review of medical records and evidence of a clinical change or addition of new medications.
Adverse Pregnancy Outcomes
Adverse pregnancy outcomes included 1 or more of the following: 1) fetal death after 12 weeks' gestation unexplained by chromosomal abnormalities, anatomical malformation, or congenital infection; 2) neonatal death before hospital discharge due to complications of prematurity, placental insufficiency (for example, abnormal fetal surveillance test results, abnormal Doppler flow velocimetry waveform analysis suggestive of fetal hypoxemia, or oligohydramnios [25] ), or both; 3) preterm delivery or termination of pregnancy at less than 36 weeks due to gestational hypertension, preeclampsia, or placental insufficiency; and 4) small-forgestational-age (SGA) neonate, defined as one with a birthweight below the fifth percentile without anatomical or chromosomal abnormalities.
Screening and Follow-up Visits
Screening evaluations included history, assessment of American College of Rheumatology criteria, physical examination, complete blood count, comprehensive metabolic panel, urinalysis, and random or 24-hour urine collection for protein-creatinine ratio (if dipstick grade was >1+). Serologic profiles (anti-dsDNA antibodies, anti-SSA/Ro antibodies, anti-SSB/La antibodies, and C3 and C4 levels) were determined at local laboratories. Tests for aPLs included anticardiolipin antibodies (IgG, IgM, and IgA), anti-␤ 2 -glycoprotein I antibodies (IgG and IgM), and lupus anticoagulant (LAC) and were performed at core laboratories (21) . Tests were repeated each trimester. The SLEPDAI and PGA were scored at the screening, second-trimester (20 to 23 weeks), and third-trimester (32 to 35 weeks) visits.
EDITORS' NOTES Context
Systemic lupus erythematosus (SLE) primarily affects women of childbearing age. Current recommendations about pregnancy in women with SLE are based on studies with methodological limitations.
Contribution
This longitudinal study enrolled and followed a multiethnic group of pregnant women with inactive or stable mild/moderate SLE at conception. Clinical and disease activity assessments and laboratory and serologic studies were performed at baseline and in each trimester.
Caution
The timing of patient enrollment precluded ascertainment of first-trimester losses.
Implication
Most pregnant patients with SLE had favorable pregnancy outcomes-few experienced severe flares. Certain clinical and laboratory variables can identify patients at high risk for adverse pregnancy outcomes.
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Statistical Analysis
We evaluated bivariate associations of APO status and each predictor variable with chi-square and Fisher exact tests for categorical variables and the t test for continuous variables. Multivariable analyses were conducted using logistic regression models. Three separate models were fit to allow for greater flexibility in modeling the potentially time-varying relationship between predictors that were measured repeatedly during pregnancy and APOs. Model 1 included variables measured at screening to identify baseline characteristics that are predictive of an APO occurring at any time. Model 2 considered these baseline variables plus variables measured at 20 to 23 weeks to predict APOs after 23 weeks, and model 3 considered additional variables measured at 32 to 35 weeks to predict late APOs. Decisions on variable selection at each step of model development were based on both clinical factors and statistical significance. For example, change in C3 level is routinely monitored in patients with SLE and was therefore prioritized for inclusion in models 2 and 3. When a continuous variable, such as PGA score, yielded similar results whether it was dichotomized using a clinically justified cut point or the original scale was used, we chose the more clinically interpretable binary form. Ethnicity/race was dichotomized to nonHispanic white versus all other groups because of sample size and clinical considerations. We also evaluated potential confounding by enrollment site. The c-statistic was computed to assess the ability of the model to discriminate between patients with and without APOs. Leave-one-out cross-validation was conducted to evaluate the degree of overfitting of the model to the data (26) .
We excluded 4 patients who were lost to follow-up. Missing data in the predictor variables was addressed using the Markov-chain Monte Carlo multiple imputation approach (SAS procedure PROC MI). The rates of missing data were 0% to 7% for baseline variables, 2% to 24% for variables at 20 to 23 weeks, and 5% to 27% for variables at 32 to 35 weeks. The imputation model included the outcome variable; all predictors in each logistic regression model; variables with missing values at the relevant visit for that model; and the following auxiliary variables deemed to influence the missing data value: history of renal disease, thrombosis, thrombocytopenia, fetal death, and heparin use for model 1; and platelet count, PGA score, SLEPDAI score, and C3 level at the prior visits for models 2 and 3. Forty imputed data sets were generated for each model, and results were combined with PROC MIANALYZE. To evaluate the robustness of our results, we conducted sensitivity analyses using the complete-case approach for handling missing data, simpler imputation models that included final predictors and the outcome variable only, and more complex imputation models. All analyses were performed using SAS, version 9.4 (SAS Institute). We defined statistical significance as a 2-sided P value less than 0.05.
Role of the Funding Source
The funding source had no role in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication.
RESULTS
Study Population and Pregnancy Outcomes
Of 741 pregnant women screened for PROMISSE, 385 patients with SLE with documented outcomes were included (Appendix Figure) . Patients were recruited from 9 sites. Forty-eight percent were non-Hispanic white, and 35% were African American or Hispanic white. Patients had inactive or stable mild/moderate SLE at entry, with a mean SLEPDAI score of 2.8 (SD, 3.0) and a mean PGA score of 0.39 (SD, 0.54). Urinary protein excretion at entry was less than 500 mg/d in 91%. Among 120 patients with a history of renal disease, available biopsy results indicated 19 with class III lupus nephritis, 29 with class IV, 21 with class V, 8 with class III and IV, and 2 with class IV and V.
One or more APOs occurred in 19.0% (CI, 15.2% to 23.2%) of patients with SLE. Fetal death occurred in 4%, neonatal death in 1%, indicated preterm delivery in 9%, and SGA in 10% (Figure and Table 1 ). Seventeen patients (4.4%) had more than 1 outcome. Preeclampsia after 36 weeks (not included in the PROMISSE APO definition) occurred in 2%. Rates of APOs were 15.4% (CI, 11.7% to 19.7%) in patients with SLE without aPLs and 43.8% (CI, 29.5% to 58.8%) in those with aPLs. In contrast, 3% (CI, 1.1% to 6.4%) of PROMISSE control participants had 1 or more APOs. Congenital heart block occurred in 1 of 154 anti-Ro-exposed fetuses. Neonatal outcomes are presented in Appendix Table 1 (available at www.annals.org).
Bivariate Analyses of Risk Factors for APOs
Demographic Characteristics and Medical History
Compared with mothers without APOs, those with APOs were more likely to be African American and to have a body mass index greater than 30 kg/m 2 , prior fetal death after more than 10 weeks' gestation, prior renal disease, and prior thrombosis ( Table 2) . Rates of APOs also differed according to the enrollment site, reflecting inherent differences in the clinical and demographic characteristics of patients treated at those centers.
Laboratory Values at the Screening Visit
The proportion of mothers classified as aPLpositive was higher among those with APOs than among those without. Mothers with APOs were more likely at screening to be LAC-positive and have a low platelet count and low complement level (C3, C4, or CH50 level below the normal laboratory value), although overall mean levels of C3 and C4 were in the normal range and did not differ significantly between those with or without an APO. The proportions of patients with anti-dsDNA antibodies, anti-Ro antibodies, anti-La antibodies, and urinary protein excretion greater than 500 mg/d were also similar across groups.
Medications and Disease Activity at the Screening Visit
Baseline SLEPDAI and PGA scores were significantly higher in patients with APOs. Use of antihypertensive medications and heparin was also more common among patients with APOs. Of 33 patients receiving antihypertensive medications, 13 had no evidence of prior nephritis and 28 had no proteinuria. Of 83 patients receiving any type of heparin, 29 met study criteria for aPL positivity and 26 had prior thrombosis. Glucocorticoids were not associated with APOs. Table 3 summarizes disease activity measures and laboratory variables obtained at 20 to 23 weeks on 370 patients who were still pregnant at 23 weeks, as well as variables measured at 32 to 35 weeks for 318 patients who were still pregnant at 35 weeks. Among patients with known flare status, 12.7% (CI, 9.4% to 16.5%) had a mild or moderate flare and 2.5% (CI, 1.1% to 4.7%) had a severe flare at 20 to 23 weeks; 9.6% (CI, 6.5% to 13.5%) had a mild or moderate flare and 3.0% (CI, 1.4% to 5.6%) had a severe flare at 32 to 35 weeks. Severe flares included nephritis (n = 9), pleuritis (n = 6), arthritis (n = 5), thrombocytopenia (n = 3), cerebritis (n = 1), myositis (n = 1), and pericarditis (n = 1), with some patients having more than 1 organ system involved. Error bars represent 95% confidence bounds. APO = adverse pregnancy outcome; LAC = lupus anticoagulant; PGA = Physician's Global Assessment; PROMISSE = Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus; SGA = small-for-gestational-age (birthweight below fifth percentile); SLE = systemic lupus erythematosus. * These patients were non-Hispanic white, were LAC-negative, had a PGA score ≤1, had a platelet count ≥100 × 10 9 cells/L, and were not treated with antihypertensive medications at baseline. They constitute a subset of "all SLE." † Because women enrolled in the PROMISSE control group had ≥1 successful pregnancy, no history of fetal death, <2 miscarriages at <10 weeks' gestation, and no underlying medical problems requiring treatment, their pregnancy outcomes were anticipated to be better than those in unselected healthy women, particularly nulliparous women. In addition to the APOs in the graph, the healthy control participants had 10 (5.1%) adverse outcomes that did not meet the study primary outcome definition: 2 genetic terminations at ≤23 wk; 3 premature preterm ruptures of membranes and/or spontaneous preterm births, 2 placental abruptions, and 1 delivery for fetal indications (supraventricular tachycardia and hydrops) at >23 to ≤35 wk; and 3 premature preterm ruptures of membranes and/or spontaneous preterm births at >35 wk (some women had >1 adverse outcome). ‡ From references 27 and 28. Not available for preterm birth as defined in the study. § Defined as delivery at <36 wk and indicated by gestational hypertension, preeclampsia, or placental insufficiency. Figure 1 shows pregnancy outcomes in the healthy control population. † Birthweight below the fifth percentile. ‡ GHTN/PE at >36 wk (n = 2) and oligohydramnios (n = 1). § Elective.
Maternal Disease Activity During Follow-up
Complete heart block (n = 1) and trisomy 18 (n = 1). ¶ GHTN/PE at >36 wk (n = 12) and oligohydramnios (n = 16). ** Placental abruption (n = 1) and poor obstetric history (n = 1). † † Chorioamnionitis (n = 3) and poor obstetric history (n = 2). ‡ ‡ SLE flares. § § Thrombocytopenia (n = 5) and congestive heart failure (n = 1). 
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At 20 to 23 weeks and at 32 to 35 weeks, smaller increases in C3 levels from baseline, higher SLEPDAI scores, and higher PGA scores were observed in patients with APOs. Platelet counts were also significantly lower at 20 to 23 weeks in those with APOs. Patients with APOs were more likely to have had a flare in the second or third trimester. Although rare, an increase in proteinuria greater than 500 mg/d from the prior visit during the second or third trimester was not associated with a subsequent APO. Anti-dsDNA antibodies and C4 levels in the second or third trimester did not differ between patients with or without APOs.
Multivariable Analysis for Risk Factors for APOs
Baseline variables that were independently predictive of APOs at any time included LAC status, antihypertensive use, PGA score greater than 1, and lower platelet count (Table 4 [ model 1] ). Non-Hispanic white ethnicity/race was associated with a lower risk for APOs compared with the other ethnic/racial groups com- and/or anti-␤ 2 -glycoprotein I IgG levels ≥40 GPL units and/or anti-␤ 2 -glycoprotein I IgM levels ≥40 MPL units at least twice between 6 wk and 5 y apart, of which one must have been during the PROMISSE study pregnancy at a core laboratory, as previously described (21) . § C3 and/or C4 level below normal value in local laboratory. bined. Lupus anticoagulant status and antihypertensive use were strongly related to risk for APOs. Similar baseline predictors of APOs were identified in analyses restricted to primigravid patients (results not shown).
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Variables at screening that predicted APOs after 23 weeks were identical to those at any time: antihypertensive use, LAC status, PGA score greater than 1, and lower platelet count, with non-Hispanic white ethnicity/ race associated with lower risk for APOs (Table 4 [model 2]). In addition, maternal flares in the second trimester, increase in SLEPDAI score, and smaller increase in C3 level from baseline predicted APOs after 23 weeks. Adjusted odds of an APO were nearly 6-fold higher among women who had a severe flare compared with those who did not.
Many baseline and second-trimester variables associated with risk for an APO were also predictive of APOs after 35 weeks, but the reduced sample size and number of events diminished power (Table 4 [model 3]). Statistically significant predictors were antihypertensive use at screening, LAC status, lower platelet count, and occurrence of a severe flare between 32 and 35 weeks. The magnitudes of the effects of nonHispanic white ethnicity/race, PGA score greater than 1, and change in C3 level on risk for APOs were similar to those in models 1 and 2 but not did reach statistical significance. The limited sample size and number of events may not support a model with this number of covariates; thus, these results should be interpreted cautiously.
In sensitivity analyses using alternative approaches for handling missing data, the main results and inferences remained the same for models 1 and 2. Model 3 was more sensitive to how missing data were handled, but baseline antihypertensive use, lower platelet count, and severe flare in the third trimester were consistently predictive of APOs after 35 weeks across the different approaches considered (Appendix Tables 2 through 4, available at www.annals.org).
Among 129 women known to be non-Hispanic white, not receiving antihypertensive therapy, and LACnegative and known to have a PGA score of 1 or lower at screening and a platelet count of at least 100 × 10 9 cells/L, only 10 (7.8% [CI, 3.8% to 13.8%]) had an APO at any time, and the fetal or neonatal death rate was 3.9% (CI, 1.3% to 8.8%). In contrast, the APO rate was 58.0% (CI, 43.2% to 71.8%) and the fetal or neonatal death rate was 22.0% (CI, 11.5% to 36.0%) in the combined group of 50 women known to be either LACpositive or LAC-negative but nonwhite or Hispanic and treated with antihypertensive medications. Seven of 8 LAC-positive patients who had a PGA score greater than 1, were receiving antihypertensive medication, or had a platelet count less than 100 × 10 9 cells/L at screening had an APO.
DISCUSSION
In our large cohort of prospectively followed patients with inactive or stable mild/moderate SLE at conception, 81% of pregnancies were uncomplicated, 5% ended in fetal or neonatal death, and severe maternal flares occurred in fewer than 3%. Of note, the rate of APOs was less than 8%, with fetal or neonatal deaths accounting for fewer than half of these events in nonHispanic white women who were LAC-negative, had a PGA score of 1 or lower, were not treated with antihypertensives, and had a platelet count of at least 100 × 10 9 cells/L. The frequency of congenital heart block was half the reported rate of 2% (29, 30), perhaps 
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due to a protective effect of hydroxychloroquine (31, 32) . Physicians often use anti-dsDNA antibodies and complement levels to anticipate clinical outcomes. In this study, anti-dsDNA positivity was not associated with APOs. However, patients with APOs more often had baseline complement levels below normal ranges, although mean C3 and C4 levels in the first trimester were in the normal range and were not predictive of APOs. Although mean levels of C3 and C4 remained in the normal range as pregnancy progressed, a smaller increase in C3 levels from baseline to the second trimester was predictive of an APO after 23 weeks. Interpretation of complement levels is confounded in pregnancy because circulating complement reflects both synthesis (enhanced by estrogen) and consumption (33) . The absence of an increase in complement levels during pregnancy suggests increased complement activation with generation of anaphylatoxins, which drive poor placental vascularization and trophoblast injury (34) .
Other studies of pregnant women with SLE have assessed serologic variables. In a single-center study of 40 pregnancies in women with mild or moderate lupus activity, clinical and laboratory variables evaluated between 20 and 28 weeks revealed that 9 of 38 live births were preterm with a low C4 level, the only marker associated with this outcome (19) . A retrospective study of 267 pregnancies in 203 non-Hispanic patients with SLE, one third of whom had APOs, showed that clinical and serologic activity (positive for anti-dsDNA antibodies or low complement level) in the second trimester was associated with fetal loss and preterm birth, even in those with low clinical activity (11) . Our observations suggest that low complement levels in the second and third trimesters were not predictive, but compared with women without an APO, those with an APO had a smaller increase in C3 level later in pregnancy compared with the baseline level.
Findings from PROMISSE suggest that patients with a history of nephritis have an increased risk for APOs, although the association was not significant in multivariable analyses. A retrospective study of 107 pregnancies in 83 patients with SLE found higher frequencies of preterm delivery (30%) and preeclampsia (28%) in women with prior nephritis compared with 11% and 16%, respectively, in women without prior nephritis (11) . Other retrospective studies did not find a relationship between prior nephritis and APOs, and the inclusion of more than 1 pregnancy in the same patient detracts from the reliability of the studies (7, 35) . Although a recent prospective study limited to patients with prior lupus nephritis concluded that patients with quiescent disease at conception had favorable pregnancy outcomes (36), a meta-analysis of 37 studies with 1842 patients showed that prior nephritis was associated with higher rates of preeclampsia (37) .
We acknowledge limitations of our study. The predictive models have not been externally validated, and the number of adverse events in model 3 was limited. 
